ArticleAnnals of burns and fire disasters2021
Prevalence Of Multidrug-Resistant Bacteria Isolated From Burn Wounds In Algeria.
Article in Annals of burns and fire disasters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 10 citations in OpenAlex.
- Pseudomonas aeruginosa: associated pathogenesis, epidemiology, resistance mechanisms, host response and emerging treatment strategies.Archives of microbiology · 2026Review
- Prevalence and Determinants of Multi-Drug Resistance Bacterial Infection Among Burn Patients in a Tertiary Care Center in Nepal.Infection and drug resistance · 2026Article
- Epidemiology and timing of infectious complications from battlefield-related burn injuries.Burns : journal of the International Society for Burn Injuries · 2024Article
- Multidrug-Resistant Organisms: The Silent Plight of Burn Patients.Journal of burn care & research : official publication of the American Burn Association · 2024Review
- Healthcare-Associated Infections' Characteristics Among Burn Patients and Risk Factors of Mortality: A Study Based on Data From a Tertiary Center in Iran: Nosocomial Infections Among Burn Patients.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2024Article
- ARAG, an Antioxidant-Rich Gel, Shows Superiority to Mepilex Ag in the Treatment of Deep Partial Thickness Burns without Sacrificing Antimicrobial Efficiency.Antioxidants (Basel, Switzerland) · 2023Article
- In Silico Study for Algerian Essential Oils as Antimicrobial Agents against Multidrug-Resistant Bacteria Isolated from Pus Samples.Antibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We conducted a thirty-four-month retrospective study in the Burns Center from June 2015 to 30 April 2018. A total of 1585 burn wound swabs were taken from 258 admitted patients, of both sex and average age from 2 to 84 years old. Out of the 1585 burn wound swabs, 79.12% were positive for bacterial growth. Gram-negative bacteria were the most common bacteria isolated from burn wound swabs (68.95%), followed by cocci gram positive (28.62%), which were represented mainly by Staphylococcus spp. and Enterococcus spp. species, and then other species such as candida spp. (2.41%). Staphylococcus aureus was found to be the most common isolate (of the 70 Staphylococcus aureus, 52 were methicillino-resistant MRSA) followed by Pseudomonas aeruginosa (n=58; 25.71%), Klebsiella pneumoniae (n=43; 20.15%), Acinetobacter baumannii (n=18; 18.70%), Proteus spp. (n=17; 7.91%), Escherichia coli (n=14; 5,75%), Enterobacter spp. (n=8; 3.22%), Candida spp. (n=6, 2.41%), Stenotrophomonas maltophilia (n=2; 1.73%), and lastly Enterococcus spp. and Citrobacter freundii (n=1; 1.73%). P. aeruginosa was the most frequent Gram-negative bacteria isolated (33.91%). Most of the species isolated were multidrug-resistant (MDR). Knowledge of the bacteria responsible for infectious complications and their antibiotic susceptibilities is a prerequisite for treating burn patients.
Indexed as
Identifiers
34584503PMC8396157W3202481432What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.